Envoy Medical Expands Patent Portfolio with New Issuances in the United States
Envoy Medical (NASDAQ: COCH), a hearing health company, has strengthened its intellectual property portfolio with two new U.S. patent issuances. The first patent (No. 12,318,607) covers methods for compensating middle ear sensor variability through analog and digital filtering. The second patent (No. 12,318,613) involves signal analysis functionality in fully implantable cochlear implant systems using external devices.
The company's technology focuses on developing fully implanted hearing solutions that eliminate external components and utilize the ear's natural anatomy for sound detection, differentiating it from traditional hearing aids and partially implanted systems.
Envoy Medical (NASDAQ: COCH), un'azienda specializzata nella salute uditiva, ha rafforzato il suo portafoglio di proprietà intellettuale con l'assegnazione di due nuovi brevetti statunitensi. Il primo brevetto (n. 12.318.607) riguarda metodi per compensare la variabilità dei sensori dell'orecchio medio attraverso filtraggi analogici e digitali. Il secondo brevetto (n. 12.318.613) riguarda la funzionalità di analisi del segnale in sistemi di impianti cocleari completamente impiantabili che utilizzano dispositivi esterni.
La tecnologia dell'azienda si concentra sullo sviluppo di soluzioni uditive completamente impiantate che eliminano componenti esterni e sfruttano l'anatomia naturale dell'orecchio per la rilevazione del suono, distinguendosi così dagli apparecchi acustici tradizionali e dai sistemi parzialmente impiantati.
Envoy Medical (NASDAQ: COCH), una empresa dedicada a la salud auditiva, ha fortalecido su portafolio de propiedad intelectual con la emisión de dos nuevas patentes en EE. UU. La primera patente (No. 12,318,607) cubre métodos para compensar la variabilidad del sensor del oído medio mediante filtrado analógico y digital. La segunda patente (No. 12,318,613) se refiere a la funcionalidad de análisis de señales en sistemas de implantes cocleares totalmente implantables que utilizan dispositivos externos.
La tecnología de la empresa se enfoca en desarrollar soluciones auditivas completamente implantadas que eliminan componentes externos y aprovechan la anatomía natural del oído para la detección del sonido, diferenciándose de los audífonos tradicionales y los sistemas parcialmente implantados.
Envoy Medical (NASDAQ: COCH)는 청력 건강 회사로서 두 건의 미국 특허 취득을 통해 지적 재산권 포트폴리오를 강화했습니다. 첫 번째 특허(번호 12,318,607)는 아날로그 및 디지털 필터링을 통한 중이 센서 변동성 보상 방법을 다루고 있습니다. 두 번째 특허(번호 12,318,613)는 외부 장치를 사용하는 완전 이식형 인공와우 시스템의 신호 분석 기능에 관한 것입니다.
회사의 기술은 외부 부품을 제거하고 귀의 자연 해부학을 활용하여 소리를 감지하는 완전 이식형 청력 솔루션 개발에 중점을 두어, 기존 보청기 및 부분 이식형 시스템과 차별화됩니다.
Envoy Medical (NASDAQ : COCH), une entreprise spécialisée dans la santé auditive, a renforcé son portefeuille de propriété intellectuelle avec l'obtention de deux nouveaux brevets américains. Le premier brevet (n° 12 318 607) porte sur des méthodes de compensation de la variabilité des capteurs de l'oreille moyenne via un filtrage analogique et numérique. Le second brevet (n° 12 318 613) concerne la fonctionnalité d'analyse du signal dans des systèmes d'implants cochléaires entièrement implantables utilisant des dispositifs externes.
La technologie de l'entreprise se concentre sur le développement de solutions auditives entièrement implantées qui éliminent les composants externes et exploitent l'anatomie naturelle de l'oreille pour la détection du son, ce qui la distingue des aides auditives traditionnelles et des systèmes partiellement implantés.
Envoy Medical (NASDAQ: COCH), ein Unternehmen im Bereich Hörgesundheit, hat sein geistiges Eigentumsportfolio mit zwei neuen US-Patenterteilungen erweitert. Das erste Patent (Nr. 12.318.607) umfasst Methoden zur Kompensation der Variabilität von Mittelohrsensoren durch analoge und digitale Filterung. Das zweite Patent (Nr. 12.318.613) bezieht sich auf Signalanalysefunktionen in vollständig implantierbaren Cochlea-Implantat-Systemen unter Verwendung externer Geräte.
Die Technologie des Unternehmens konzentriert sich auf die Entwicklung vollständig implantierbarer Hörlösungen, die externe Komponenten eliminieren und die natürliche Anatomie des Ohrs zur Schallerkennung nutzen, wodurch sie sich von herkömmlichen Hörgeräten und teilimplantierten Systemen unterscheidet.
- Two new U.S. patents strengthen intellectual property portfolio
- Technology offers unique fully implanted solution without external components
- Patents demonstrate continued innovation in hearing health technology
- None.
Insights
Envoy Medical strengthens its competitive position with two strategic patents enhancing its fully implantable cochlear technology.
Envoy Medical's announcement of two new U.S. patents represents a meaningful enhancement to their intellectual property portfolio in the hearing health space. The first patent (No. 12,318,607) addresses a critical technical challenge by introducing methods to compensate for variability in middle ear sensors through advanced filtering techniques. This innovation could potentially improve sound quality and consistency in their fully implanted cochlear systems.
The second patent (No. 12,318,613) establishes methods for external signal analysis within a fully implantable system - essentially creating a diagnostic capability that allows clinicians to monitor and optimize device performance without compromising the fully-implanted nature of the technology.
These patents align strategically with Envoy's core differentiation in the hearing health market: fully implanted solutions that eliminate external components while leveraging natural ear anatomy. This approach represents a fundamental departure from conventional hearing aids and partially-implanted systems currently dominating the market.
The timing of these patents is particularly relevant as the hearing health industry faces increasing pressure for innovation beyond traditional form factors. By securing intellectual property that addresses both technical performance (signal normalization) and clinical utility (diagnostic capabilities), Envoy strengthens its competitive moat in the specialized but growing fully-implantable hearing solution segment.
White Bear Lake, Minnesota--(Newsfile Corp. - July 8, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced the issuance of two new patents, further strengthening its intellectual property portfolio in the United States.
The U.S. Patent & Trademark Office has issued two additional patents to Envoy Medical:
- U.S. Patent No. 12,318,607, on June 3, 2025. The title of the patent is Implantable Cochlear System with Integrated Components and Lead Characterization. Aspects of this patent relate to methods of compensating for variability in a middle ear sensor. Input signals from a middle ear sensor representing received stimulus signals are filtered using analog and digital filters, and the digital filter is adjusted to normalize the frequency response of the digitally filtered signals with respect to the stimulus signals across a plurality of frequencies or frequency ranges.
- U.S. Patent No. 12,318,613, on June 3, 2025. The title of the patent is Implantable Cochlear Implant System with Integrated Signal Analysis Functionality. Aspects of this patent involve using an external device to designate a signal within a fully implantable cochlear implant system for analysis and to receive a representative signal from the cochlear implant system. The external device outputs a representation of the signal for analysis by a user.
"We believe these recent patent issuances further demonstrate our team's ability to innovate and push boundaries in hearing health," said Brent Lucas, CEO of Envoy Medical.
Envoy Medical's fully implanted technologies are designed to eliminate external components and leverage the natural anatomy of the ear for sound detection, offering a fundamentally different experience from traditional hearing aids or partially implanted systems.
For more information about Envoy Medical's innovation pipeline and intellectual property portfolio, visit www.envoymedical.com.
To be added to the Envoy Medical email distribution list, please email Envoy@kcsa.com with COCH in the subject line.
About Envoy Medical, Inc.
Envoy Medical (NASDAQ: COCH) is a hearing health company focused on providing innovative technologies across the hearing loss spectrum. Envoy Medical has pioneered one-of-a-kind, fully implanted devices for hearing loss, including its fully implanted Esteem® active middle ear implant, commercially available in the U.S. since 2010, and the fully implanted Acclaim® cochlear implant, an investigational device. Envoy Medical is dedicated to pushing hearing technology beyond the status quo to improve access, usability, compliance, and ultimately quality of life.
About the Fully Implanted Acclaim® Cochlear Implant
We believe the fully implanted Acclaim Cochlear Implant ("Acclaim CI") is a first-of-its-kind hearing device. Envoy Medical's fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound.
The Acclaim CI is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim CI is expected to be indicated for adults who have been deemed adequate candidates by a qualified physician.
The Acclaim Cochlear Implant received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019.
CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use.
About the Esteem® Fully Implanted Active Middle Ear Implant (FI-AMEI)
The Esteem fully implanted active middle ear implant (FI-AMEI) is the only FDA-approved, fully implanted* hearing device for adults diagnosed with moderate to severe sensorineural hearing loss allowing for 24/7 hearing capability using the ear's natural anatomy. The Esteem FI-AMEI hearing implant is invisible and requires no externally worn components and nothing is placed in the ear canal for it to function. Unlike hearing aids, you never put it on or take it off. You can't lose it. You don't clean it. The Esteem FI-AMEI hearing implant offers true 24/7 hearing.
*Once activated, the external Esteem FI-AMEI Personal Programmer is not required for daily use.
Important safety information for the Esteem FI-AMEI can be found at: https://www.envoymedical.com/safety-information.
Additional Information and Where to Find It
Copies of the documents filed by Envoy Medical with the SEC may be obtained free of charge at the SEC's website at www.sec.gov.
Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-Looking statements may be identified by the use of words such as "estimate," "plan," "project," "forecast," "intend," "will," "expect," "anticipate," "believe," "seek," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. Such statements may include, but are not limited to, statements regarding the expectations of Envoy Medical concerning the outlook for its business, productivity, plans and goals for future operational improvements and capital investments; the ability to obtain additional patents and develop future products or product improvements, the Acclaim CI being the first to market fully implanted cochlear implant, the timing and results of approvals, site documents, logistics, activations, enrollments, follow-up visits, data, and clinical trials of the Acclaim CI, and the participation or any changes in participation of any subjects, institutions, or healthcare professionals in such trials; the safety, performance, and market acceptance of the Acclaim CI; the size of Envoy Medical's addressable market, operational performance, future market conditions or economic performance and developments in the capital and credit markets and any information concerning possible or assumed future operations of Envoy Medical. The forward-looking statements contained in this press release reflect Envoy Medical's current views about future events and are subject to numerous known and unknown risks, uncertainties, assumptions and changes in circumstances that may cause its actual results to differ significantly from those expressed in any forward-looking statement. Envoy Medical does not guarantee that the events described will happen as described (or that they will happen at all). These forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to changes in the market price of shares of Envoy Medical's Class A Common Stock; changes in or removal of Envoy Medical's shares inclusion in any index; Envoy Medical's success in retaining or recruiting, or changes required in, its officers, key employees or directors; unpredictability in the medical device industry, the regulatory process to approve medical devices, and the clinical development process of Envoy Medical products; competition in the medical device industry, and the failure to introduce new products and services in a timely manner or at competitive prices to compete successfully against competitors; disruptions in relationships with Envoy Medical's suppliers, or disruptions in Envoy Medical's own production capabilities for some of the key components and materials of its products; changes in the need for capital and the availability of financing and capital to fund these needs; changes in interest rates or rates of inflation; legal, regulatory and other proceedings could be costly and time-consuming to defend; changes in applicable laws or regulations, or the application thereof on Envoy Medical; a loss of any of Envoy Medical's key intellectual property rights or failure to adequately protect intellectual property rights; the effects of catastrophic events, including war, terrorism and other international conflicts; and other risks and uncertainties set forth in the section entitled "Risk Factors" and "Cautionary Note Regarding Forward Looking Statements" in the Annual Report on Form 10-K filed by Envoy Medical on March 31, 2025, and in other reports Envoy Medical files, with the SEC. If any of these risks materialize or Envoy Medical's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While forward-looking statements reflect Envoy Medical's good faith beliefs, they are not guarantees of future performance. Envoy Medical disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes after the date of this press release, except as required by applicable law. You should not place undue reliance on any forward-looking statements, which are based only on information currently available to Envoy Medical.
###
Investor Contact:
Phil Carlson
KCSA Strategic Communications
O: 212.896.1233
E: pcarlson@kcsa.com
SOURCE: Envoy Medical, Inc.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/258045
FAQ
What new patents did Envoy Medical (NASDAQ: COCH) receive in 2025?
How does Envoy Medical's hearing technology differ from traditional solutions?
What is the purpose of Envoy Medical's Patent No. 12,318,607?
What functionality does Envoy Medical's Patent No. 12,318,613 cover?
Who is the CEO of Envoy Medical (NASDAQ: COCH)?
